A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects

Hong Zhang; Hong Chen; Xiaojiao Li; Min Wu; Xiaoxue Zhu; Cuiyun Li; Jingrui Liu; Haijing Wei; Yue Hu; Jingjing Wang; Yongmin Yang; Xiangyang Zhu; Yanhua Ding

doi:10.3389/fphar.2021.646171

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects

Front Pharmacol. 2021 Mar 17:12:646171. doi: 10.3389/fphar.2021.646171. eCollection 2021.

Authors

Hong Zhang¹, Hong Chen¹, Xiaojiao Li¹, Min Wu¹, Xiaoxue Zhu¹, Cuiyun Li¹, Jingrui Liu¹, Haijing Wei¹, Yue Hu¹, Jingjing Wang², Yongmin Yang², Xiangyang Zhu², Yanhua Ding¹

Affiliations

¹ Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
² Shanghai Huaota Biopharmaceutical Co., Ltd., Shanghai, China.

Abstract

Objective: This study explored the bioequivalence of a proposed biosimilar HOT-3010 vs. its reference product (adalimumab) among healthy Chinese male subjects. The study also investigated the tolerance, immunogenicity, and pharmacokinetics (PK). Methods: A randomized, double-blind, two-arm, parallel study was performed to examine the bioequivalence of HOT-3010 (40 mg) with that of adalimumab (Humira^®, AbbVie) as a reference drug. The study subjects were followed up for 71 days. Results: PK properties exhibited by HOT-3010 (N = 66) and adalimumab (N = 68) groups were similar. The 90% confidence intervals of the ratios for C _max, AUC_0-t , and AUC_0∞ were observed to be in the range 80-125% on comparing the two groups. For anti-drug antibodies (ADA), the number of subjects found to be positive in the HOT-3010 group and adalimumab group were 29 (43.94%) and 32 (47.06%), whereas 27 (40.91%) and 27 (39.71%) subjects were found to be positive for NAb, respectively. Treatment-related treatment-emergent adverse events (TEAEs) were recorded in 32 subjects each in both the groups, respectively. Conclusion: The PK characteristics and immunogenicity exhibited by HOT-3010 were similar to that of the reference product, adalimumab. The safety profiles were similar in both the treatment groups with mild-moderate adverse effects.

Keywords: adalimumab; biosimilar; immunogenicity; intersubject variability; pharmacokinetics.